PITTSBURGH (PRWEB)
June 07, 2023

PredxBio, the leading company in Spatial Biology and Explainable AI for predicting the progression of disease, has announced the appointment of Brad Spitz, MBA, as its Chief Commercial Officer. In this role, Brad will drive the company’s commercial growth strategy, lead global sales and business development efforts, and further expand PredxBio’s presence in the biopharma industry.

Dusty Majumdar, PhD, CEO of PredxBio, stated, “With Brad’s extensive expertise in driving commercial excellence and his proven track record of executing strategies at scale, he is the perfect candidate to lead our global commercial team in the upcoming phase of growth. His leadership will be instrumental in taking our proprietary Explainable AI-powered Spatial Biology analytics solutions to new heights of adoption in the biopharma industry. Having successfully grown businesses for renowned life science and biopharma companies over the past two decades, Brad brings invaluable experience to our team and his appointment as Chief Commercial Officer positions the company for accelerated growth, forging impactful partnerships, and furthering the adoption of innovative solutions in spatial biology and cutting-edge analytics!”

Brad Spitz is a highly accomplished and versatile executive in the life sciences industry, with a wealth of experience across various sectors including biotech, pharmaceuticals, molecular diagnostics, academia, digital pathology, AI, and oncology healthcare. His impressive career includes a 19-year tenure at Johnson & Johnson, where he held roles in multiple operating companies such as Ethicon, Ortho-Clinical Diagnostics, Veridex, and Janssen Diagnostics. During his time at Johnson & Johnson, Brad played a pivotal role in pioneering CellSearch©, one of the earliest liquid biopsy tests in oncology designed to measure circulating tumor cells. Brad has also held Vice President of Sales positions at esteemed companies such as ANGLE Plc., Orbis Biosciences (Acquired by Adare Pharma Solutions), and Congenica, showcasing his expertise in driving sales growth and building successful commercial strategies. In addition to his industry experience, Brad has been involved with the prestigious Mayo Clinic as part of the BioPharma Dx team and most recently served at PaigeAI. Brad holds an MBA from Elon University and a bachelor’s degree with double majors in Economics and Communications from the University of Wisconsin, Madison.

“This is an incredibly exciting moment for me as I join the remarkable team at PredxBio and become an integral part of their mission. I am thrilled to have the opportunity to bring this game-changing Spatial Biology technology to the market in a truly transformational way,” said Brad Spitz. “Integrity, resiliency, and building great relationships will be at the core of my efforts to help grow this company. I am deeply passionate about leading the fight against cancer, and I cannot wait to collaborate with our key stakeholders at PredxBio and our BioPharma partners to leverage the power of spatial biology in delivering innovative therapies that will positively impact the lives of patients. I am honored to be a part of this journey and look forward to bringing our pioneering solutions to the market as we unlock the true power of spatial biology.”

The PredxBio platform seamlessly integrates multimodal data, such as spatial proteomics, spatial transcriptomics, and brightfield pathology, to uncover the hidden circuitries of tumor microenvironments and reveal the complex network biology of cancer. By performing highly scalable, Explainable AI (xAI) powered spatial analyses of diverse imaging techniques, PredxBio generates actionable insights for biomarker discovery, identifying drug targets, and designing effective clinical trials. Through the quantification of cell-cell interactions, identification of intermediate cell types and states, and discovery of microdomains, PredxBio delves into the organizing principles of spatial intratumor heterogeneity, providing a mechanistic understanding of tumor initiation, progression, and response to therapy. This comprehensive platform drives personalized therapeutic options, improving prediction accuracies based on spatial tumor biology and enabling optimal treatment selection for individual patients. With the launch of the PredxBio brand, we establish our leadership position in Spatial Biology, uniquely capable of predicting patient outcomes with 90%+ accuracy by unraveling the hidden biological circuitries of cancer.

About PredxBio

PredxBio is a Pittsburgh, PA-based company focused on the development of explainable AI-powered spatial analytics software platforms to decipher the complex cancer biology and bend the survival curve for immunotherapy cancer patients. PredxBio’s solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. PredxBio has already completed engagements with early paying customers including pharma partners who are harnessing PredxBio’s solutions to assess treatment response in immunotherapy.

http://www.predxbio.com

Share article on social media or email:

BOSTON (PRWEB)
May 30, 2023

Andrew (A.J.) Tibbetts, shareholder at global law firm Greenberg Traurig, LLP, will moderate a panel, “IP for AI: Expanding a Biopharma IP Portfolio to Protect AI and Data Innovations,” at the 2023 BIO International Convention June 6.

The panel will discuss various intellectual property (IP) options for protecting investments and developments in artificial intelligence (AI), software, and data science in the biopharma industry, for small, mid-size, and large companies, as well as founders, executives, and counsel in biopharma.

Tibbetts, an IP & Technology shareholder in the firm’s Boston office, leverages prior experience as a software engineer to provide practical intellectual property strategy counseling on matters related to software-implemented tech across a range of industries, from networking, fintech, and natural language processing through to life sciences, artificial intelligence, medical records, and medical devices. He advises a wide array of clients on intellectual property strategies, ranging from international and publicly traded companies and large research institutions to small and growing companies. He serves on the board of directors of MassMEDIC, helping support digital health efforts in the New England area.

About Greenberg Traurig’s Intellectual Property & Technology Practice: With more than 260 intellectual property attorneys and patent agents in the United States, Asia, and Europe, Greenberg Traurig provides a broad range of patent, trademark and copyright protection and strategic counseling. Greenberg Traurig was named a “National Tier 1” Law Firm for IP Litigation, Patent Law and Litigation, Copyright Law, Technology Law, and Information Technology Law by U.S. News and Best Lawyers, 2023 “Best Law Firms.” In addition, Greenberg Traurig was named a “Law Firm of the Year” for Trademark Law in the 2020 and 2022 editions of “Best Law Firms.” The BTI Consulting Group named Greenberg Traurig’s IP Litigation Practice a ‘Litigation Standout’ in the “BTI Litigation Outlook 2023: Litigation Spending in the Uncertain Economy and Beyond.”

About Greenberg Traurig: Greenberg Traurig, LLP has more than 2650 attorneys in 45 locations in the United States, Europe and the Middle East, Latin America, and Asia. The firm is a 2022 BTI “Highly Recommended Law Firm” for superior client service and is consistently among the top firms on the Am Law Global 100 and NLJ 250. Greenberg Traurig is Mansfield Rule 5.0 Certified Plus by The Diversity Lab. The firm is recognized for powering its U.S. offices with 100% renewable energy as certified by the Center for Resource Solutions Green-e® Energy program and is a member of the U.S. EPA’s Green Power Partnership Program. The firm is known for its philanthropic giving, innovation, diversity, and pro bono. Web: http://www.gtlaw.com.

Share article on social media or email:

WHEATON, Ill. (PRWEB)
May 12, 2023

Team PHenomenal Hope, a national nonprofit advocacy organization, is proud to announce its inaugural symposium, PHenomenal Hope 2023: Knowledge, Research & Advocacy in PH to be held on Friday, December 15, 2023 in Boston, Massachusetts at the Omni Boston Hotel at the Seaport.

Established experts, thought leaders, young investigators and healthcare providers committed to advancing clinical science and care in the field of pulmonary hypertension are invited to share original research. This symposium offers a combination of oral presentations, expert panel discussions, and poster sessions in an environment that encourages collaboration and a deeper exploration of patient-centered research. Attendees will have the opportunity to network with colleagues and other healthcare professionals throughout the day.

Abstract submissions are being accepted through the registration website at PAH2023.com until August 1, 2023. Submissions should focus on unique research while recognizing and understanding the unmet needs in research and patient care through disease modification and clinical trial design.

“Team PHenomenal Hope has grown exponentially in recent years and is excited to bring forward this new research symposium with the support of our premier sponsor and others to collaborate and focus on patient-centered research,” shared Team PH Board Chair Dr. Harrison Farber.

“At Janssen, we are deeply committed to supporting scientific advancement and revolutionizing the patient experience. Team PHenomenal Hope has identified a new opportunity for the PH community that aims to inspire continued innovation and collaboration, and we are proud to be the premier sponsor of this research symposium,” said Samuele Butera, President, US Pulmonary Hypertension and Retina at the Janssen Pharmaceutical Companies of Johnson & Johnson.

For more information and to register for PHenomenal Hope 2023: Knowledge, Research & Advocacy in PH, visit PAH2023.com.

About Team PHenomenal Hope

Team PHenomenal Hope’s mission is to fund medical research into improved treatments or a cure for those who suffer from pulmonary hypertension and to implement programs and services that remove patients from isolation, build community, and provide hope. To learn more about Team PH, visit http://www.teamph.org.

Share article on social media or email:

AUSTIN, Texas (PRWEB)
April 19, 2023

KetoCon 2023 will take place at The Palmer Center in Austin from April 21-23. Q1 Productions, a leader in wellness-centric events, will organize the conference series focusing on the benefits of utilizing ketosis, biohacking, sleep hygiene, and various nutritional protocols to improve metabolic health. One of the breakout session speakers for this year’s event will be Martha Carlin.

Martha is a nationally recognized expert in gut health and microbiome research who founded The BioCollective to advance research on gut bacteria and health. She will present her talk “How Gut Health Impacts Insulin Resistance, Metabolic Output, and Ketosis” on Friday, April 21, at 1:40 pm on Breakout Stage 1. During the talk, she will discuss how gut health is integral to achieving optimal metabolic outcomes and how it can help impact insulin resistance in those following a keto lifestyle.

In addition to the presentations, this year’s event will feature an exhibition hall with multiple vendors showcasing their latest products and innovations related to keto lifestyle topics, such as probiotics. BiotiQuest, Carlin’s brand, which offers revolutionary probiotics for better gut health, will be an exhibitor.

Attendees of KetoCon 2023 can stop by booth 526 to learn more from BiotiQuest about their products and how they can support a healthy microbiome and overall health.

KetoCon 2023 allows attendees to learn about the benefits of a keto lifestyle while networking with vendors devoted to creating products centered around good metabolic health. Speakers at this year’s event, such as Ben Azadi, Dr. Mindy Pelz, and more, bring years of knowledge and experience that can provide valuable insights into achieving their health goals and maintaining a healthy lifestyle. This conference series promises something for everyone looking to enhance their lives through physical well-being, so mark your calendars now for KetoCon 2023!

Share article on social media or email:

BOSTON (PRWEB)
April 06, 2023

Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, today announced the addition of Neil Butera as chief commercial officer. This hire deepens the bench of the C-suite team in response to the company’s continued growth.

“We are thrilled to have Neil join the Syner-G team,” said Ron Kraus, chief executive officer, Syner-G. “His proven commercial experience in the bio-tech industry is an invaluable asset to the current leadership team. We look forward to seeing the unique ways he will propel our services while contributing to our culture of guiding clients to a healthier tomorrow.”

Neil’s previous experience includes 15 years at Parexel where he held Business Development roles within the Clinical Research & Regulatory Consulting business units before becoming the executive director, Global Head of Inside Sales for Parexel’s Biotech division. His organization helped Parexel Biotech secure over $1 billion in new business awards.

Before Parexel, Neil was director of business development for Ockham Development Group. During his professional career he also held board seats for many children-based non-profit organizations and in 2012, Neil cofounded ‘It’s About Caring for Kids’ where he still serves as Chairman of the Board. He is married with three children and continues to be a positive influence in his community.

“I am honored to be chosen as the new chief commercial officer for Syner-G,” said Neil Butera. “It is exciting to be a part of this innovative company whose services underpin the successful development of lifesaving therapies across the biopharma industry.”

Read more about Neil Butera on LinkedIn here.

About Syner-G BioPharma Group

Based in Boston, MA, Syner-G is a leading provider of customized CMC, regulatory strategy, medical writing, regulatory submissions and publishing services, supporting pharmaceutical and biotechnology companies across the therapeutic spectrum and complete drug development lifecycle. For more information, please visit: https://synergbiopharma.com/

Share article on social media or email:

WAYNE, Pa. (PRWEB)
April 04, 2023

RCH Solutions, Inc., a leading provider of scientific computing Consulting, Professional, and Managed Services exclusively for Life Sciences teams, has announced its participation in the 22nd annual Bio-IT World Conference and Expo, May 16th – 18th at the Hynes Convention Center in Boston, MA. The long-standing event will bring together scientists, researchers, and technology experts from the Life Sciences space to discuss the latest IT and technology innovations in drug research, discovery and development.

“We are thrilled to participate in Bio-IT World 2023, an important industry event that has always been a valuable opportunity for face-to-face collaboration in the Life Sciences,” said Michael Riener, CEO of RCH Solutions. “Our team is excited to again connect with industry colleagues and friends—old and new— and share how our science-centered Bio-IT solutions can help organizations address their complex compute challenges.”

To drive additional connection and collaboration, RCH Solutions and long-time partner 20/15 Visioneers will host an evening of cocktails and hors d’oeuvres at their private event, ‘Cocktails and Computing’, following day 1 of the Bio-IT World Event & Expo. The event will provide a valuable opportunity to connect with peers and discuss the latest trends and opportunities driving Bio-IT success within companies large and small.

Where to Connect with RCH Solutions at Bio-IT World 2023

At the event, you can find RCH at booth 911, where their team will be on-hand to share how it’s driving successful customer outcomes—from project inception through execution—by way of its comprehensive suite of scientific, Cloud and technical computing solutions, including their unique Sci-T Consulting, Professional and Managed Services support offerings. For more than 30 years, the company’s services have helped start-up, emerging and global Life Science organizations design, build and tune optimized compute environments that enable R&D teams to accelerate innovation in drug discovery and development.

“We look forward to sharing our knowledge and experiences with the attendees of Bio-IT World 2023,” added Riener. “This event provides an excellent opportunity for us to connect with our colleagues and industry peers, and showcase how RCH can help organizations optimize their environments to achieve their goals.”

RCH’s sponsorship and strong presence at Bio-IT World this year, combined with their recently established MassBio membership demonstrates their continued Boston-area focus, and their rapidly growing demand as an industry leading Bio-IT provider in the Life Sciences.

To learn more about RCH Solutions and its unmatched suite of scientific computing solutions, find their team at booth 911 and register for their private event, ‘Cocktails and Computing’ while space lasts.

Contact:

Melissa Thomas

215-499-9788

media@rchsolutions.com

About RCH Solutions:

RCH Solutions (RCH) is a global provider of Bio-IT expertise, helping Life Sciences and Healthcare companies of all sizes clear the path to discovery. For more than 30 years, RCH has provided focused experience and unmatched specialization designing and deploying cross-functional IT strategies, supporting R&D infrastructure, and offering workflow best practices that solve enterprise and scientific computing challenges. Learn more at http://www.rchsolutions.com

Share article on social media or email: